UNSPSC 51422343: Dexamethasone tebutate

This classification denotes a therapeutic glucocorticoid and antiemetic agent C28H39FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8IPA7Z9N7Y, chemically known as 9-fluoro-11.beta.,17,21-trihydroxy-16.alpha.-methylpregna-1,4-diene-3,20-dione 21-(3,3-dimethylbutyrate), but more generally known as dexamethasone tebutate, which bears US NIH Compound Identifier 20055086. European Medicines Agency schedules Dexamethasone tebutate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01618MIG.

Most nations, for tariff and trade purposes, schedule dexamethasone tebutate under HS 29372200 and SITC 54153. As of Q4 2014, DEXAMETHASONE TEBUTATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)CC(C)(C)C)O)C)O)F)C.

UNSPSC 51422343 Dexamethasone tebutate is a Commodity code for a specific corticosteroid medication, but recent state and local procurement activity tagged to this code shows a mismatch with its nominal scope. The single recent opportunity in the dataset—Seminole County, Florida's IFB for naloxone and safe drug deactivation systems—does not involve dexamethasone tebutate procurement. The county's solicitation targets opioid-reversal medication and drug disposal systems to support community health initiatives, a distinct pharmaceutical category. This divergence suggests either a data-entry error in the code assignment or limited recent activity under the actual dexamethasone tebutate commodity.

The mismatch between the code's name and the Seminole County opportunity limits visibility into genuine procurement patterns for dexamethasone tebutate at the state and local level. No other recent opportunities in the dataset reference this specific medication. Without additional solicitations correctly tagged to this Commodity code, current market signals for dexamethasone tebutate demand, issuing-body mix, or geographic concentration cannot be established. Business development professionals should verify whether their target jurisdictions maintain separate purchasing streams for this corticosteroid through medical supply contracts, group purchasing organizations, or standing healthcare agreements rather than relying on this code's recent activity.